Monica Montag, Holistic Nutritionist, on Endorphinate

Monica Montag, Founder of BeWell Associates and Holistic Nutritionist, has found that Endorphinate provides remarkable benefits for their clients suffering from a wide variety of emotional and physical problems.  Here is an article from BeWell Associates:


Anxiety, Addiction, and Pain…Oh My!


Anxiety, addiction and pain are the triple whammy of our culture and our times.

Wouldn’t it be great if we could just make them vanish with a pill?  Really? Is that even possible?

Although I can’t promise that everyone will receive complete relief from these three afflictions I can say that many will.  Studies by national healthcare experts  and our own survey reflects the same results.  We have been testing a product for a local psychologist, Dr. Steven Crain, who developed a new product called Endorphinate, with the assistance of his scientist father.

I have started using it myself, although I do not suffer from anxiety, addiction (well, maybe chocolate and coffee!) or chronic pain.  But I wanted to test it myself.  I can tell you that I feel more calm and more energized at the same time, consistently throughout the day.

The secret is in the formula, which is a combination of familiar vitamins, minerals and botanicals that are blended in a unique proportion.  This combination helps balance and regulate the chemicals in our nervous system, specifically focusing on the chemicals called endorphins, which control our perceptions of stress and pain.  So, even though all the old triggers that may push your buttons remain, your reaction to them is reduced.  This transformation in reactivity has potentially profound and powerful effects on long term stress-induced health issues that now can be avoided or reduced.

Endorphinate not only helps us to be less reactive to external negative triggers, but also enhances our pleasure sensations.   By balancing these powerful brain chemicals we can break out of the cycle of chronic stress reactivity, unbalanced cortisol, and the fatigue, anxiety and general lack of joy and contentment that is so common in many peoples’ daily lives.

There are far reaching benefits of managing these brain chemicals that go beyond decreased anxiety, enhanced energy, and clear thinking. One of my first clients who tried it had numerous ailments that we initially attributed to food allergies.  However, upon further testingwe found that they were not allergy related and yet, this young woman was down to eating an extremely limited diet.  After a week or so on the Endorphinate, all her suspected food allergies cleared up. Since then she has been able to eat a normal range of foods without discomfort.

The Endorphinate rebalanced her brain chemistry and eliminated the extreme anxiety that was actually causing those reactions.  And after a few months of using the product, she has been able to discontinue it, because it had lasting effects on her brain chemistry.

Since then I am seeing numerous clients whose digestive problems resolve on just 1-2 Endorphinate each day.  This improvement in digestion makes a great deal of sense to me, given how intimately we experience stress through our digestive system.  The production of an adequate supply of digestive enzymes diminishes with stress and hence affects our ability to digest and assimilate food. When stress is reduced, digestion improves.

Stress also makes us hungry.  Endorphinate has a powerful effect on decreasing the cravings that are associated with unbalanced cortisol (the stress hormone) levels.  We are seeing weight loss in some folks who have been struggling otherwise, and they feel much more emotionally even as a bonus!

We have a few wives who won’t let their husbands’ supply run out…and some husbands who do the same for their wives!  I don’t know of any relationship that could not benefit from a little more tolerance and patience, and I find the Endorphinate helps this happen.

We are in the process of evaluating how Endorphinate  effects blood sugars.  The stress response increases not only cortisol but also blood sugar levels.  Decreasing cortisol has the potential to normalize blood sugar. If you are a diabetic who checks blood sugars at least once/day and would like to try this product, please let us know.  We will be happy to give you the first bottle free in exchange for blood sugar data!   Just email me for the particulars:

The original formula’s ingredients include the active form of B6 (P-5-P), folic acid, B12,   magnesium, ashwaganda (the Indian ginseng), gingko (increases circulation to the brain), NAC (powerful anti-oxidant),  guarana, l-theanine, and  lemon balm.

In summary, here is what you can expect from Endorphinate:

  • All natural ingredients
  • Unique endorphin balancing formulation
  • Relieves emotional and physical distress
  • Promotes calm, comfort, and well‑being
  • Enhances positive mood
  • Reduces cravings
  • Reduces addiction
  • Increases energy and mental clarity
  • Boosts immune system

Endorphinate comes in different formulas:

  • Endorphinate AR is the original.
  • Endorphinate CF is the same as the original formula but without caffeine (unless you are VERY sensitive to caffeine I recommend you use the original formula- the caffeine is minimal and really enhances the effect).
  • Endorphinate PR is the pain relief formula.

If you need to take a second dose do so by mid afternoon.  It is safe to use in conjunction with SSRI’s and SNRI’s.   It is not necessarily needed on an ongoing basis.

Posted in Uncategorized | Comments Off on Monica Montag, Holistic Nutritionist, on Endorphinate

New Article on Science of Endorphinate

This is an abstract of an article that will be published in the Journal of Behavioral and Brain Science, which summarizes the decades of scientific studies that validate the discoveries upon which Endorphinate is based:

Endorphinergic Attenuation of Distress Dysfunctions by Concomitantly Enhancing Endogenous Opioid Release and Switching Opioid Receptor Signaling from an Excessively Excitatory to a Normal Inhibitory Mode1

Steven Crain, PhDa and Stanley M. Crain, PhDb

aTherapeutic Alliance, State College, PA  16801, USA                                

bDept. of Neuroscience, Albert Einstein College of Medicine,

Yeshiva University, Bronx, NY  10461, USA


There is increasing evidence that the endogenous opioid system has a significant role in the etiology of a wide variety of previously considered distinct clinical distress dysfunction disorders, including chronic anxiety, depression, addiction, anger, autism, and pain, though the mediating processes have been elusive.  Many types of clinical distress dysfunction disorders show interesting similarities to the excitatory autonomic withdrawal effects in chronic opioid-dependent animals and humans, as well as to the “quasi-morphine withdrawal syndrome” that is evoked in naïve rodents shortly after acute systematic injection of a cyclic AMP-phosphodiesterase (cAMP-PDE) inhibitor (e.g., theophylline or caffeine).  These symptoms appear to be caused by excessive excitatory opioid receptor signaling as well as reduced endorphin production.

Well-documented pharmacologic analyses of the remarkably plastic bimodal (excitatory/inhibitory) properties of opioid receptor functions, have been carried out, at first, by analyses of intracellular microelectrode recordings from opioid-sensitive neurons in tissue cultures of mouse dorsal root ganglia attached to spinal cord cross-sections and subsequently in vivo, utilizing hot-water tail-flick assays in mice.  These coordinated in vitro and in vivo studies have led to discovery of specific chemical formulations that switch opioid receptor signaling from an excessively excitatory to a normal inhibitory mode. This groundbreaking discovery has been validated in large clinical pain trials, which demonstrate the remarkable ability of opioid receptor “switchers” to reduce serious emotional and physical distress symptoms typically produced by exogenous opioid use.

Critically formulated combinations of cAMP-PDE inhibitors (e.g., rolipram or caffeine) that release endorphins, together with specific agents (e.g, ultra-low-dose naltrexone) that switch opioid receptors from excitatory Gs-coupled to inhibitory Gi/Go-coupled molecular pathways have been shown to elicit endorphinergic attenuation of hyperalgesia and distress evoked by diverse chemical stressors (e.g., very low-dose opioids, cAMP-PDE inhibitors, elevated GM1 ganglioside), thereby enhancing thermal pain tolerance and reducing distress in mouse tail-flick assays. Both the “quasi-morphine withdrawal syndrome” in naïve rodents as well as the excitatory withdrawal effects in chronic, opioid-dependent animals and humans may, indeed, be extreme manifestations of common clinical distress dysfunction disorders, including chronic anxiety, addiction, and pain.  We suggest that endorphinergic attenuation of a wide variety of distress dysfunction disorders can be significantly enhanced by concomitantly increasing endogenous opioid release and switching excessively excitatory (Gs-coupled) opioid receptor signaling to normal inhibitory (Gi/Go-coupled) signaling throughout the entire central and peripheral nervous system.

This combination of endorphin enhancers with opioid receptor “switchers” provides a completely novel method to attenuate emotional and physical distress using naturally occurring endogenous rather than exogenous opioids or other non-specific pharmaceuticals with numerous noxious side effects.  These discoveries are consistent with recent neural imaging studies, which reveal the critical role of excessive activation of the limbic system, especially the amygdala, in a variety of neuropsychiatric disorders, and the high prevalence of endorphins in these stress/emotion-related brain centers.  There is also increasing evidence that endorphinergic imbalances are produced by a wide variety of factors, including prolonged stress, illness, certain drugs and chemicals, processed food, unhealthy lifestyles, and genetic vulnerabilities.  Recent sophisticated analyses that reflect the critical role of endorphins in the complex inter-relationships among stress/emotion-related neurotransmitter systems, including dopamine, serotonin, GABA, and norepineprhine, also support the potential therapeutic benefits of restoring healthy endorphinergic balance to the brain and gut.

Pilot trials of critically formulated oral nutraceutical preparations, containing both endorphin enhancers (e.g., caffeine, ginkgo biloba) and opioid receptor “switchers” (e.g., N-acetyl cysteine, magnesium sulfate) have resulted in marked long-term anxiolytic efficacy and enhanced calming and mood-elevating effects while simultaneously promoting mental clarity and a remarkably adaptive response to stress in large numbers of individuals with distress dysfunction symptoms. These new insights into specific dysfunctional processes underlying clinical distress disorders will stimulate a new generation of endorphinergic formulations which safely restore normal homeostatic balance to the complex endogenous opioid system, thereby resolving the neurophysiologic dysfunction underlying a variety of previously considered distinct neuropsychiatric disorders including chronic anxiety, depression, addiction, anger, autism, and pain.

1Full article to be published, by invitation, in the Journal of Behavioral and Brain Science (JBBS, ISSN:2160-5874)

Posted in Uncategorized | Comments Off on New Article on Science of Endorphinate

In Memoriam of Dr. Ke-Fei Shen; died November 17, 2012

In Memoriam of Dr. Ke-Fei Shen; died November 17, 2012

(by Dr. Stanley M. Crain, Professor Emeritus, Albert Einstein College of Medicine)

I met Ke-Fei in 1980 at the “Shanghai Workshop on Neurobiology”, an historic conference at the Brain Research Institute in Shanghai.  The Chinese National Academy of Sciences had invited me, along with a dozen U.S. and European neuroscientists, in order to update 100 young Chinese neuroscientists (including Dr. Shen) on recent trends in Western neuroscience research.  This conference was co-sponsored by the U.S. National Academy of Sciences and provided the first official contact between U.S. and Chinese neuroscientists after many years of intellectual isolation during the brutal Chinese “cultural revolution!”

I was about 57 years old during my visit to Shanghai and among the bright young Chinese neuroscientists at the conference was Dr. Ke-Fei Shen, who was then 48 and already established as a prominent leader of the Shanghai Brain Research Institute.  He was evidently inspired by my lecture about utilizing electrophysiologic analyses of nerve tissue cultures to analyze the mechanisms of action of opioids.  In collaboration with Dr. Eric Simon (co-discoverer of opioid receptors), we had recently demonstrated that sensory-evoked dorsal-horn synaptic networks discharges in organotypic tissue cultures of mouse spinal cord with attached dorsal root ganglia were selectively depressed by perfusion with a series of exogenous and endogenous opioids, at concentrations remarkably proportionate to their potency in the intact animal (Crain et al, Brain Research, 1978).

Several years later, I received a letter from the director of the Shanghai Brain Research Institute indicating that Dr. Shen would like to visit my laboratory at the Albert Einstein College of Medicine en route from a 6-month visiting research scholarship in France.  Dr. Shen arrived in my lab around 1985 and he was so impressed with our opioid research projects that he decided to prolong his visit for “a while”.  Ke-Fei and I interacted so well together that he finally made a crucial decision to join my laboratory and cancel his prior commitment to return to the Shanghai Brain Research Institute!

Dr. Shen skillfully initiated a series of elegant electrophysiologic analyses of opioid effects on dorsal-root ganglion neurons in our organotypic cord-ganglion tissue cultures, utilizing intracellular microelectrode techniques that I had developed many years earlier (Crain, Journal of Comparative Neurology, 1956).  Within a year we were able to obtain significant experimental evidence that opioids could evoke not only well-known inhibitory signaling effects but also novel excitatory signaling in action potential of the same sensory neuron.  These excitatory effects were shown to be selectively elicited by >1,000-fold lower opioid concentrations than required to elicit inhibitory effects.  Excitatory opioid effects were selectively enhanced by application of pharmacologic agents that increase the cyclic AMP levels in these neurons (Shen & Crain, Brain Research, 1989).  This seminal paper stimulated a remarkable series of pharmacologic and biochemical studies initially aimed at molecular mechanisms underlying these novel opioid-evoked excitatory effects in sensory neurons and subsequently applied to broader problems, e.g. opioid-induced hyperalgesia, tolerance and dependence (published in Brain Research, PNAS, Pain and other prominent journals).  After a decade of microelectorode analyses of opioid effects on sensory neurons in vitro, Dr. Shen and I began in 1995 another decade of significant pharmacologic behavioral studies of analgesia and hyperalgesia in mice, utilizing antinociception and hyperalgesia hot-water tail-flick assays.  These studies led to our discovery of novel methods to attenuate tolerance and dependence during chronic opioid treatment of mice as well as pain patients by co-treatment with ultra-low-dose naltrexone or neuraminidase inhibitors of GMI ganglioside.

Finally, we demonstrated that a significant degree of opioid-like analgesia could be elicited in mice without the use of exogenous opioids.  Naïve mice were injected with cyclic AMP-phosphodiesterase inhibitors, e.g., rolipram or caffeine, resulting in hyperalgesia and the release of endogenous opioids, i.e., endorphins.  Subsequent injection of ultra-low-dose naltrexone resulted in the rapid onset of opioid-mediated (naltrexone-reversible) analgesia (Crain & Shen, Brain Research, 2008).

Dr. Shen and I were, indeed, delighted to have had the opportunity to demonstrate this animal model of endorphinergic analgesia as the culmination of our research projects at the Albert Einstein College of Medicine!  This study also provided the pharmacologic rationale for development of novel clinical treatments of severe emotional and physical distress dysfunction disorders, including chronic anxiety, addiction, and pain, in collaboration with my son , Dr. Steven Crain, a clinical psychologist.  Successful pilot studies have recently been carried out with a dietary endorphinergic formulation (Endorphinate®) developed by Pondera Pharmaceuticals Inc.

Dr. Shen’s pioneering intracellular microelectrode analyses of the bimodal excitatory/inhibitory functions of opioid receptors in sensory neurons in tissue culture have, indeed, provided remarkably fruitful insights into complex behavioral activities of the entire nervous system, far beyond our wildest expectations when we started this collaborative project in the 1980’s!

— by Dr. Stanley M. Crain, Professor Emeritus, Albert Einstein College of Medicine


Posted in Uncategorized | Comments Off on In Memoriam of Dr. Ke-Fei Shen; died November 17, 2012